Polyene phosphatidylcholine for liver function improvement in liver-injury patients: A multicenter retrospective study

Abstract

Objective: To investigate the heterogeneous effects of polyene phosphatidylcholine (PPC) on different liver diseases.

Methods: This multicenter retrospective study used the Cooperative Registry of Hospital Prescription from 264 Grade-A hospitals in 16 provinces in China. Eligible patients had abnormal baseline liver functions and follow-up liver function tests. We used linear mixed-effects growth curve analysis to analyze the change of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT) and total bilirubin after adjusting for age and sex. Statistical significance was set at P<0.05.

Results: Among 1 454 patients (median age 52 years; 63.8% male), PPC significantly controlled abnormal ALT, AST, GGT and total bilirubin (P<0.05). Patients with drug-induced liver injury exhibited higher baseline ALT levels and more rapid ALT decline. Cirrhotic patients had lower baseline ALT/AST and slower recovery. Patients with alcoholic liver disease had a sharp GGT decline (P<0.001). ALT/AST recovery was not impacted by autoimmune hepatitis. Patients with higher baseline ALT received higher PPC doses, resulting in an adequate ALT/AST normalization time.

Conclusions: PPC’s hepatoprotective effects differed by liver disease subtypes. Higher doses suited patients with elevated baseline ALT/AST.

Keywords

Polyene phosphatidylcholine / Liver function / Liver injury / Liver disease

References

[1] Zhang J, Zang X, Lv J, Zhang Y, Lv Z, Yu M. Changes in lipidomics, metabolomics, and the gut microbiota in CDAA-induced NAFLD mice after polyene phosphatidylcholine treatment. Int J Mol Sci 2023; 24(2): 1502.

[2] He YH, Ou LL, Jiang JL, Chen YF, Abudukeremu A, Xue Y, et al. Bletilla striata polysaccharides alleviate metabolic dysfunction-associated steatotic liver disease through enhancing hepatocyte RelA/HNF1α signaling. World J Gastroenterol 2025; 31(4): 93179.

[3] Cao M, Li X, Zhang B, Han S, Yang Y, Zhou B, et al. The effect of polyene phosphatidyl choline intervention on nonalcoholic steatohepatitis and related mechanism. Am J Transl Res 2016; 8(5): 2325-2330.

[4] Li Y, Chen A, Li Z, Cui X, Zhang G. Effectiveness of polyene phosphatidylcholine and its combination with other drugs in patients with liver diseases based on real-world research. Expert Rev Clin Pharmacol 2022; 15(11): 1363-1375.

[5] Lei X, Zhang J, Xu Q, Li J, Qian Y, Zhang J, et al. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: A propensity score matching comparison. J Int Med Res 2021; 49(8): 3000605211039810.

[6] Jin Y, Liu T, Tong Z, Dong M. Analysis of the efficacy of polyenyl phosphatidylcholine in combination with liraglutide in nonalcoholic fatty liver disease and the effect of omentin-1 and vaspin expression. Altern Ther Health Med 2025; 31(4): 273-277.

[7] Lu Y, Feng T, Zhao J, Jiang P, Xu D, Zhou M, et al. Polyene phosphatidylcholine ameliorates high fat diet-induced non-alcoholic fatty liver disease via remodeling metabolism and inflammation. Front Physiol 2022; 13: 810143.

[8] Lei P, Cao L, Zhang H, Fu J, Wei X, Zhou F, et al. Polyene phosphatidylcholine enhances the therapeutic response of oxaliplatin in gastric cancer through Nrf2/HMOX1 mediated ferroptosis. Transl Oncol 2024; 43: 101911.

[9] Du Y, Gu J, Yang Y, Chen Y, Wang Y, Mei Z, et al. Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury. Int J Tuberc Lung Dis 2024; 28(1): 6-12.

[10] Gundermann KJ, Gundermann S, Drozdzik M, Mohan Prasad VG. Essential phospholipids in fatty liver: A scientific update. Clin Exp Gastroenterol 2016; 9: 105-117.

[11] Niu H, Atallah E, Alvarez-Alvarez I, Medina-Caliz I, Aithal G P, Arikan C, et al. Therapeutic management of idiosyncratic drug-induced liver injury and acetaminophen hepatotoxicity in the paediatric population: A systematic review. Drug Saf 2022; 45(11): 1329-1348.

[12] Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ, et al. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARα-null mice through attenuation of increases in oxidative stress. J Hepatol 2009; 50(6): 1236-1246.

[13] Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610.

[14] Xu J, Fan Y, Yu Y, Han Y, Kang Q, Tan N, et al. A multicenter real-world study evaluating the hepatoprotective effect of polyene phosphatidylcholine against chronic hepatitis B. Front Med (Lausanne) 2022; 9: 842098.

[15] Li WHS, Shen HM, Jin Y, Zuo MZ. Analysis on utilization of medical resource of original and imitative medium/long chain fat emulsion injection of propofol. Eval Ana Drug Use Hosp Chin 2019; 19(12): 1491-1493, 1499.

[16] Curran PJ, Obeidat K, Losardo D. Twelve frequently asked questions about growth curve modeling. J Cogn Dev 2010; 11(2): 121-136.

[17] Muthén BOCP. General longitudinal modeling of individual differences in experimental designs: A latent variable framework for analysis and power estimation. Psychol Methods 1997; 2(4): 371-402.

[18] Allison PD. Handling missing data by maximum likelihood in SAS conference proceedings: SAS global forum 2012. [Online]. Available from: https://statisticalhorizons.com/wp-content/uploads/MissingDataByML.pdf. [Accessed on 15 June 2026].

[19] Bender R, Lange S. Adjusting for multiple testing-when and how? J Clin Epidemiol 2001; 54(4): 343-349.

[20] Hooper R. To adjust, or not to adjust, for multiple comparisons. J Clin Epidemiol 2025; 180: 111688.

[21] Roche N, Reddel H, Martin R, Brusselle G, Papi A, Thomas M, et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc 2014; 11(Suppl 2): S99-S104.

[22] AHRQ methods for effective health care. In: Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, editors. Developing a protocol for observational comparative effectiveness research: A user's guide. [Online]. Available from: https://www.betagov.org/docs/CER%20users%20guide.pdf [Accessed on 15 June 2026].

[23] Shi D, DiStefano C, Zheng X, Liu R, Jiang Z. Fitting latent growth models with small sample sizes and non-normal missing data. Int J Behav Dev 2021; 45(2): 179-192.

[24] Valentino G, Zivko C, Weber F, Brulisauer L, Luciani P. Synergy of phospholipid-drug formulations significantly deactivates profibrogenic human hepatic stellate cells. Pharmaceutics 2019; 11(12): 676.

[25] Luchtenborg C, Niederhaus B, Brugger B, Popovic B, Fricker G. Lipid profiles of five essential phospholipid preparations for the treatment of nonalcoholic fatty liver disease: A comparative study. Lipids 2020; 55(3): 271-278.

[26] Schuppan D. Liver fibrosis: Common mechanisms and antifibrotic therapies. Clin Res Hepatol Gastroenterol 2015; 39(Suppl 1): S51-S59.

[27] Mak K M, Shekhar A C. Soybean polyenylphosphatidylcholine is beneficial in liver and extrahepatic tissue injury: An update in experimental research. Anat Rec (Hoboken) 2024; 307(6): 2162-2186.

[28] Moreira JLS, Barbosa SMB, Gonçalves J Júnior. Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review. Clin Res Hepatol Gastroenterol 2021; 45(6): 101752.

[29] Yue SR, Tan YY, Zhang L, Zhang BJ, Jiang FY, Ji G, et al. Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway. Front Endocrinol (Lausanne) 2022; 13: 885039.

[30] Colak Y, Hasan B, Erkalma B, Tandon K, Zervos X, Menzo EL, et al. Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target. Clin Res Hepatol Gastroenterol 2021; 45(4): 101710.

[31] González I, Chatterjee D. Histopathological features of drug-induced liver injury secondary to osimertinib. ACG Case Rep J 2019; 6(2): e00011.

[32] Zhu W, Zhang X, Yu M, Lin B, Yu C. Radiation-induced liver injury and hepatocyte senescence. Cell Death Discovery 2021; 7(1): 244.